drugset / Trial / NCT04848974
Uproleselan, Cladribine, and Low Dose Cytarabine for the Treatment of Patients With Treated Secondary Acute Myeloid Leukemia
Non-randomizedSingle-groupOpen-labelTreatment
Summary
This phase Ib/II trial finds out the best dose and effect of cladribine and low dose cytarabine when given in combination with uproleselan in treating patients with treated secondary acute myeloid leukemia. Chemotherapy drugs, such as uproleselan, cladribine, and low dose cytarabine, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading.
Timeline
- Start
- 2021-06-11
- Primary completion
- 2024-10-30
- Completion
- 2024-10-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cladribine | Small molecule | 3.75 mg/m2 | Intravenous |
| Subject | Cladribine | Small molecule | 5 mg/m2 | Intravenous |
| Subject | Cytarabine | Small molecule | — | Subcutaneous |
| Subject | Uproleselan | Small molecule | — | Intravenous |